The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV

AIDS Patient Care and STDs

Volumn 23, Issue 11, 2009, Pages 939-947

  Kapetanovic, Suad ^a   Aaron, Lisa ^b   Montepiedra, Grace ^b   Sirois, Patricia A ^c   Oleske, James M ^d   Malee, Kathleen ^e   Pearson, Deborah A ^f   Nichols, Sharon L ^g   Garvie, Patricia A ^h   Farley, John ⁱ   Nozyce, Molly L ^j   Mintz, Mark ^k   Williams, Paige L ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j BRONX LEBANON HOSPITAL CENTER   (United States)

^k Clinical Research Center of New Jersey   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROTEINASE INHIBITOR; QUETIAPINE; RISPERIDONE; VIRUS RNA; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; CHILD; CHILD GROWTH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PSYCHOPHARMACOTHERAPY; SIDE EFFECT; VIRUS LOAD; WEIGHT CHANGE;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANTIPSYCHOTIC AGENTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MENTAL DISORDERS; TREATMENT OUTCOME;

EID: 72849127436     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0121     Document Type: Article

References (38)

1. Monasch R, Mahy M. Young people: The centre of the HIV epidemic. World Health Organ Tech Rep Ser 2006;938:15-41; discussion 317-341.
2. Saharan S, Lodha R, Agarwal R, Deorari AK, Paul VK. Perinatal HIV. Indian J Pediatr 2008;75:359-362.
3. Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM. Quality of life for children and adolescents: Impact of HIV infection and antiretroviral treatment. Pediatrics 2006; 117:273-283.
4. Storm DS, Boland MG, Gortmaker SL, et al. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics 2005;109:e61.
5. Butler A, Williams P, Howland L, Hutton A, Storm D, Seage GR III. Disclosure of HIV infection status and health-related quality of life in children with HIV infection. Pediatrics 2009;123;935-943.
6. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. July 29, 2008; pp. 1-134. http:==aidsinfo.nih.gov= ContentFiles= PediatricGuidelines.pdf (Last accessed February 22, 2009).
7. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089. (Pubitemid 29452821)
8. Venerosi A, Calamandrei G, Alleva E. Animal models of anti-HIV drugs exposure during pregnancy: Effects on neurobehavioral development. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:747-761.
9. Mekmullica J, Brouwers P, Charurat M, et al. Early immunological predictors of neurodevelopmental outcomes in HIV-infected children. Clin Infect Dis 2009;48:338-346.
10. Kovacs A. Early immune activation predicts central nervous system disease in HIV-infected infants: Implications for early treatment. Clin Infect Dis 2009;48:347-349.
11. Forstein M, Cournos F, Douaihy A, Goodkin K, Wainberg ML, Wapenyi KH. Guideline Watch: Practice Guideline for the Treatment of Patients with HIV= AIDS. Arlington, VA: American Psychiatric Association, 2006.
12. Donenberg GR, Pao M. Youth and HIV=AIDS: Psychiatry's role in a changing epidemic. J Am Acad Child Adolesc Psychiatry 2005;44:728-747.
13. Mellins CA, Smith R, O'Driscoll MS, et al. NIH= HIAID=NICHD=NIDA- Sponsored Women and Infant Transmission Study Group. High rates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. Pediatrics 2003;111:384-393.
14. Nozyce ML, Lee SS, Wiznia A, et al. A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006;117:763-770.
15. Malee K, Williams P, Montepiedra G, et al. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J Pediatr Psychol 2009; 34:164-175.
16. Gaughan DM, Hughes MD, Oleske JM, et al. Psychiatric hospitalizations among children and youth with HIV infection. Pediatrics 2004:113;e544-551.
17. Chernoff M, Nachman S, Williams PL, et al. Mental health interventions in HIV-Infected and uninfected children and adolescents enrolled in PACTG P1055. Pediatrics 2009;124: 627-636.
18. Martinez J, Hosek SG, Carleton RA. Screening and assessing violence and mental health disorders in a cohort of inner city HIV-positive youth between 1998-2006. AIDS Patient Care STDs 2009;23:469-475.
19. Mellins CA, Brackis-Cott E, Leu CS, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry 2009;50:1131-1138.
20. Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006;7: 1871-1885.
21. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44: 548-556. (Pubitemid 40720954)
22. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63:679-685.
23. U.S. Food and Drug Administration: FDA approves the first drug to treat irritability associated with autism, Risperdal. FDA News October 6, 2006. www.fda.gov=bbs=topics=news= 2006=new01485.html (Last accessed July 13, 2009).
24. U.S. Food and Drug Administration: FDA approves Risperdal for two psychiatric conditions in children and adolescents. FDA News August 22, 2007. www.fda.gov=bbs= topics=news=2007=NEW01686.html (Last accessed July 13, 2009).
25. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:268-274.
26. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46:687-700.
27. Fraguas D, Merchán-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008;69:1166-1175.
28. Bell LM, Byrne S, Thompson A, et al. Increasing body mass index z score is continuously associated with complications of overweight in children, even in the healthy weight range. J Clin Endocrinol Metab 2007;92:517-1222
29. Foster C, Judd A, Tookey P, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: The pediatric legacy for adult services. AIDS Patient Care STDs March 2009;23:159-166.
30. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDs 2008;22:245-251.
31. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J; International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr 2008;47:607-614.
32. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: Z-score data files. 2000.www.cdc.gov=nchs=about=major= nhanes=growthcharts= zscore=zscore.htm (Last accessed July 13, 2009).
33. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771-791.
34. Sirois PA, Montepiedra G, Kapetanovic S, et al. Impact of Medications Prescribed for Treatment of Attention Deficit-Hyperactivity Disorder on Physical Growth in Children and Adolescents with HIV. J Dev Behav Pediatr (in press).
35. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics 2001;108:E72.
36. Miller TL, Mawn BE, Orav EJ, Wilk D, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 2001;107:E77.
37. Jover F, Cuadrado JM, Andreu L, Merino J. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002;25:251-253.
38. Kelly DV, Beýqüe LC, Bowmer MI. Extrapyramidal symptoms with ritonavir=indinavir plus risperidone. Ann Pharmacother 2002;36:827-830.